Study data from J. Sevilla and colleagues update understanding of life sciences
2008 JAN 17 -- Fresh data on life sciences are presented in the report 'Early acute myeloblastic leukemia treatment for childhood myelodysplastic syndrome with t(3;5) (NPM/MLF1).' According to a study from Madrid, Spain, "Myelodysplastic syndromes (MDS) in childhood are rare hematologic diseases. MDS with t(3;5) (NPM/MLF1) is an unusual subtype without a well-defined clinical and prognostic pattern." "A poor outcome has been reported, suggesting that hematopoietic transplantation is the only treatment option. Here in we described a 2-year-old child diagnosed with the disease, without a suitable hematopoietic donor, treated early in the disease with chemotherapy. He is alive and well 4 years after the end of treatment," wrote J. Sevilla and colleagues, . The researchers concluded: "This unusual MDS needs further studies to better understand the disease." Sevilla and colleagues published the results of their research in the Journal of Pediatric Hematology (Early acute myeloblastic leukemia treatment for childhood myelodysplastic syndrome with t(3;5) (NPM/MLF1). Journal of Pediatric Hematology, 2007;29(12):839-40). For additional information, contact J. Sevilla, Oncohematologia pediatrica Hospital Nino Jesus, Madrid, Spain. The publisher of the Journal of Pediatric Hematology can be contacted at: Lippincott Williams & Wilkins, 530 Walnut St., Philadelphia, PA 19106-3621, USA. Keywords: Spain, Madrid, Life Sciences, Hematology, Myelodysplastic Syndromes, Oncology, Acute Myeloblastic Leukemia, Pediatric Hematology, Hematologic Disease, Treatment, Therapy, Transplantation, Hematopoietic. This article was prepared by Blood Weekly editors from staff and other reports. Copyright 2008, Blood Weekly via NewsRx.com.
|
